EXACT SCIENCES CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.55 USD | +4.83% |
|
+1.63% | -38.43% |
Financials (USD)
| Sales 2024 * | 2.83B | Sales 2025 * | 3.22B | Capitalization | 8.02B |
|---|---|---|---|---|---|
| Net income 2024 * | -194M | Net income 2025 * | -25M | EV / Sales 2024 * | 3.42 x |
| Net Debt 2024 * | 1.66B | Net Debt 2025 * | 1.31B | EV / Sales 2025 * | 2.9 x |
| P/E ratio 2024 * |
-41.5
x | P/E ratio 2025 * |
-442
x | Employees | 6,550 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.02% |
More Fundamentals
* Assessed data
More news
Latest transcript on Exact Sciences Corporation
More recommendations
More press releases
More news
| 1 day | +4.83% | ||
| 1 week | +1.63% | ||
| Current month | +0.22% | ||
| 1 month | -26.62% | ||
| 3 months | -22.14% | ||
| 6 months | -29.67% | ||
| Current year | -38.43% |
1 week
43.30
47.19
1 month
43.3063.79
Current year
43.3079.62
1 year
43.30100.77
3 years
29.27133.99
5 years
29.27159.54
10 years
4.67159.54
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Conroy
CEO | Chief Executive Officer | 58 | 09-03-17 |
Paul Limburg
CTO | Chief Tech/Sci/R&D Officer | - | 18-03-05 |
Jorge Garces
CTO | Chief Tech/Sci/R&D Officer | 52 | 21-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
D. Coward
BRD | Director/Board Member | 59 | 14-12-31 |
Kevin Conroy
CEO | Chief Executive Officer | 58 | 09-03-17 |
Freda Lewis-Hall
BRD | Director/Board Member | 69 | 20-04-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.80% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 45.55 | +4.83% | 2,340,944 |
| 24-06-04 | 43.45 | -3.06% | 2,368,012 |
| 24-06-03 | 44.82 | -1.39% | 2,104,648 |
| 24-05-31 | 45.45 | +0.44% | 2,144,952 |
| 24-05-30 | 45.25 | +0.96% | 2,571,711 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotes
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Companyâs products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Companyâs flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patientâs breast tumor tissue.
Calendar
2024-06-11
- Goldman Sachs Global Healthcare Conference
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
45.55
USD
Average target price
84.86
USD
Spread / Average Target
+86.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.43% | 8.02B | |
| +15.30% | 3.43B | |
| +2.34% | 2.27B | |
| -19.52% | 2.03B | |
| -20.72% | 1.63B | |
| +31.45% | 1.16B | |
| +21.58% | 714M | |
| -9.39% | 703M | |
| -21.63% | 500M | |
| -1.29% | 279M |
- Stock Market
- Equities
- EXAS Stock
